CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to Give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • Speaking With Your Oncologist: The Importance of Building Trust and Open Dialogue

    Brendan Connors and his oncologist, Michael Postow, MD, reunited for a special Cancer Immunotherapy Month webinar to…

    June 20, 2019| Sofia Balog
  • Riding with a Purpose: Answer to Cancer Studio Cycling Event

    At the second annual Answer to Cancer studio cycling event hosted by the CRI Associate Board, 36 dedicated…

    June 19, 2019| Angela Bui
  • CRI Celebrates a Future #Immune2Cancer on June 14 – Wear White Day

    Supporters, scientists, patients, and advocates participated in CRI’s annual Wear White Day for a Future Immune to…

    June 17, 2019| CRI Staff
  • “Cancer Immunotherapy Insights from ASCO” Twitter Chat Recap #CIMchat

    CRI hosted a Twitter Chat, moderated by STAT’s Sharon Begley, discussing takeaways from the ASCO19 conference last…

    June 12, 2019| Chary Sathea
  • ASCO19 Recap: Caring for Every Patient, Learning from Every Patient

    ASCO19 highlighted a number of immunotherapy developments, including those relating to long-term survival, introducing immunotherapy earlier, biomarkers,…

    June 7, 2019| Arthur N. Brodsky, PhD
  • ASCO19 Day 5 Update: CAR T Cells for Pleural Cancers and More Melanoma News

    The final day of ASCO19 covered CAR T cells for pleural cancers and long-term updates on several…

    June 5, 2019| Arthur N. Brodsky, PhD
  • ASCO19 Day 4 Update: Kidney Cancer, Liver Cancer, Stomach Cancer, Esophageal Cancer, and Melanoma

    The fourth day at ASCO19 highlighted immunotherapy strategies for patients with kidney cancer, liver cancer, stomach cancer,…

    June 3, 2019| Arthur N. Brodsky, PhD
  • ASCO19 Day 3 Update: Immunotherapy for Brain Cancer, Ovarian Cancer, Lung Cancer, and Patients with HIV

    The third day at ASCO19 highlighted immunotherapy strategies for patients with brain cancer, ovarian cancer, lung cancer,…

    June 3, 2019| Arthur N. Brodsky, PhD
  • ASCO19 Day 2 Update: Biomarkers in Checkpoint Immunotherapy, Targeting Macrophages, and Cellular Immunotherapies

    The second day at ASCO19 highlighted biomarkers that may have value in the context of PD-1 checkpoint…

    June 2, 2019| Arthur N. Brodsky, PhD
Previous Page
1 … 44 45 46 47 48 … 92
Next Page
Father and son

Join CRI in Shaping the Future of Immunotherapy

Support the pioneering work of CRI in advancing immunotherapy.

See ways to give

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to Give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute